Ocumetics Technology Corp.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ocumetics Technology Corp. is a Canadian-based ophthalmic technology company specializing in the research, development, production, and sale of advanced vision enhancement products. The company’s core product is the patented Ocumetics Accommodating Lens, an implantable intraocular lens designed to restore natural dynamic vision by mimicking the eye’s biomechanics, enabling patients to achieve clear, instantaneous focus at near, intermediate, and far distances without the need for corrective glasses or contact lenses. The lens targets primarily patients over 45 years of age, particularly those undergoing cataract surgery, with the goal of eliminating dependence on traditional corrective lenses. Founded in 2012 and headquartered in Calgary, Alberta, Ocumetics has leveraged nearly two decades of research to develop its groundbreaking Bionic Lens technology, which aims to provide seamless and adaptive vision. In recent major developments, the company initiated its first-in-human clinical trials in 2025, marking a pivotal milestone towards regulatory approval and global commercialization. These trials, conducted in Mexico City, evaluate the safety, performance, and visual outcomes of the Ocumetics Lens, with early postoperative results surpassing expectations. The company announced completion of critical milestones, including finalizing its lens design and manufacturing processes, and securing ethics committee approvals for clinical study progression. Ocumetics has recently raised additional funding through brokered financings to support its clinical and commercialization efforts. The company is strategically positioning itself to disrupt the global multi-billion-dollar lens implant market with its innovative accommodating intraocular lens technology. Ocumetics maintains a commitment to transparency, scientific rigor, and advancing ophthalmic solutions that address accommodation issues and vision deterioration associated with aging worldwide. The company was formerly known as Quantum Blockchain Technologies Ltd. before changing its name to Ocumetics Technology Corp. in August 2021 to reflect its focus on ophthalmic technologies. Ocumetics operates primarily in Canada but is preparing for wider global market entry following successful clinical validations. Its main market segments include patients with age-related vision decline and cataracts, targeting the vision care and medical device industries. Ocumetics's product and service offerings include advanced accommodating intraocular lenses designed for cataract surgery patients; vision enhancement technologies based on patented biotechnological designs; and ongoing development of next-generation ophthalmic implants that enable adaptive, naturalistic eyesight without corrective lenses.
Ocumetics Announces Significant Debt Conversion Strengthening Balance Sheet Ahead of Patient Study Milestones
Ocumetics Accelerates Toward Group Two First-In-Human Study with Manufacturing Launch of Optimized Accommodating Lens
Ocumetics Announces Offering of Units
Ocumetics Reports Improvement in Six Month First-in-Human Results Meaningful Improvements in Patient Quality of Life
Ocumetics Technology Reports Attendance at ASCRS as Successful First-In-Human Trial Continues, No Material Change
Ocumetics to Showcase First-In-human Results with Industry Leaders & Potential Strategic Partners at ASCRS Annual Meeting
Ocumetics Technology Corp. Achieves Breakthrough in Next-Generation Accommodating Intraocular Lens Design
Ocumetics Announces Issuance of Stock Options
Ocumetics Announces Scientific Advisory Committee to Support Advancing Clinical and Regulatory Strategy
Ocumetics Announces Appointment of Raymond Marks to Board of Directors
Ocumetics Announces Forbearance Agreement for $4 Million Secured Convertible Debentures and Provides LIFE Offering Update
Ocumetics Reports Positive Three Month First-in-Human Results, Significantly De-Risking Its Accommodating Intraocular Lens Technology
Ocumetics Announces Proposed Forbearance Agreement for $4 million Secured Convertible Debentures
Ocumetics Announces Transition of Chief Medical Officer Consulting Role
Ocumetics Technology Announces Closing of First Tranche of Brokered LIFE Offering Led by Centurion One Capital
Ocumetics Technology Announces Amendment to Brokered LIFE Offering Led by Centurion One Capital
Ocumetics Announces Optimized Lens Delivery System in Collaboration with Medicel
Ocumetics Technology Announces $2.5 Million Brokered LIFE Offering Led by Centurion One Capital
Ocumetics Reports Continued Improvement in First Group of Patients. Early Vision Results Surpass Expectations
Ocumetics to Present at the Centurion One Capital 3rd Annual Bahamas Summit